Market Overview

UPDATE: Credit Suisse Upgrades GlaxoSmithKline to Neutral; Pricing Policy Impact Priced In

Related GSK
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
Tracking The Hotchkis & Wiley Value Opportunities Fund - Q3 2015 Update (Seeking Alpha)

Credit Suisse raised its rating on GlaxoSmithKline (NYSE: GSK) from Underperform to Neutral.

Credit Suisse noted, "We upgrade rating of GSK to NEUTRAL from Underperform and increase our target price to Rs2,055 (from Rs1,870). Our positive stance is driven by the fact that the overhang of pricing policy is largely over, in our view, and the margins (ex-pricing policy impact) have bottomed out and should rebound. Under the new pricing policy, GSK drugs are now more affordable and should gain volume share. On the current portfolio under price control (25% of sales), the pricing policy allows players to take 10% price increase after one year and GSK should benefit."

GlaxoSmithKline closed at $43.85 on Wednesday.

Latest Ratings for GSK

Oct 2015Credit SuisseUpgradesUnderperformNeutral
Oct 2015JP MorganUpgradesUnderweightNeutral
Jun 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (GSK)

Get Benzinga's Newsletters